Replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval the potential of the Toll-like receptor 9 (TLR9) agonist technology discussed in this communication Products) the nature, timing, and possible success and therapeutic applications of Regenerons Products, product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, Regenerons ProductĬandidates), and product candidates being developed by Checkmate, such as vidutolimod the extent to which the results from the research and development programs conducted by Regeneron, Checkmate, and/or their collaborators or licensees may be SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regenerons or Checkmates business and its employees,Ĭollaborators, and suppliers and other third parties on which Regeneron and Checkmate rely Regenerons, Checkmates, and their collaborators ability to continue to conduct research and clinical programs Regenerons andĬheckmates ability to manage their supply chains Regenerons ability to manage net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, Regenerons Operating results significant transaction costs unknown liabilities the risk of litigation and/or regulatory actions related to the proposed acquisition the impact of The proposed acquisition will not be realized or will not be realized within the expected time period and that Regeneron and Checkmate will not be integrated successfully the effects of the transaction on relationships with employees, otherīusiness partners or governmental entities negative effects of this announcement or the consummation of the proposed acquisition on the market price of Regenerons or Checkmates common stock and/or Regenerons or Checkmates Governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations) the difficulty of predicting the timing or outcome of regulatoryĪpprovals or actions, if any the possibility that the transaction does not close risks related to Regenerons ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from Many of Checkmates stockholders will tender their stock in the offer the possibility that competing offers will be made the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing of the tender offer and merger uncertainties as to how expect, intend, plan, believe, seek, estimate, variations of such words, and similar expressions are intended to identify such forward-looking statements, although not allįorward-looking statements contain these identifying words. (∼heckmate), and actual events or results may differ materially from these forward-looking statements. (Regeneron) and Checkmate Pharmaceuticals, Inc. The Company's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.This communication includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron The Company is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The Company is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The Company's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |